Recalled Medicines & supplements – Current GIS Alerts 2026
Found 685 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Lorafen
The detected non-compliance in the active substance release parameter affects the quality of this medicinal product, so its impact on efficacy and safety of use cannot be excluded. Therefore, a risk to human health or life from leaving these batches on the market cannot be ruled out. Potencjalne skutki: lack of treatment efficacy, unpredictable effects, complications endangering health or life.
Carmustine Accord
The solvent, which is part of the medicine, does not meet quality requirements due to an exceeded limit of residue after evaporation, linked to leaching of substances from silicone tubing used during manufacturing. Potential effects: contamination of infusion solution, possible toxic effects or unpredictable reactions in patients.
Taromentin
In an individual carton of Taromentin 1000 mg + 200 mg (batch 2010525), a vial of Taromentin 500 mg + 100 mg (batch 1020525) was found, containing half the intended dose of active substances. A real risk to patient health due to insufficient therapeutic efficacy cannot be excluded. Potential effects: lack of treatment efficacy, risk of infection progression, disease complications.
Plerixafor MSN
This product does not meet the specified quality requirements due to a negative test result for contamination with particles visible to the naked eye. Potential effects: complications related to administration of a contaminated solution for injection.
Zoledronic Acid Noridem
NIL testing revealed visible particles in Zoledronic Acid Noridem 4 mg/5 ml concentrate for solution for infusion, meaning the product does not meet quality requirements for solution appearance. Potential effects: complications after intravenous administration, embolization by particles, inflammatory reactions.
Furaginum MAX US Pharmacia
Testing by the National Medicines Institute showed non-compliance with quality requirements for the parameter "nitrosamine content: NDMA" and did not exclude NDMA contamination in product batches. Potential effects: exposure to a genotoxic nitrosamine, possible adverse effects and reduced safety of therapy.
Skinsept Mucosa
During long-term stability testing of batch 2434LH0503, an out-of-specification result was obtained for a single unidentified impurity and a borderline result for impurity K relative to specification limits. Potential effects: reduced product quality, uncertain efficacy and safety of therapy.
Syntarpen
Risk of microbiological contamination detected in the manufacturing environment of Syntarpen, powder for solution for injection. For a parenteral product, such non-conformities may translate into increased risk to patients' health. A threat to life cannot be excluded. Potential effects: infection, sepsis, severe parenteral complications, life-threatening events.
Locametz
Non-compliance with quality requirements was found: the level of a single unknown impurity in batch PG21PL2505 exceeded the acceptable limit set in the product specification, which may affect safety of use and represents a real threat to human health. Potential effects: possible adverse reactions, therapy complications or other unpredictable effects related to the presence of the impurity.
Egoropal
Routine FDA inspection revealed serious deficiencies in aseptic manufacturing processes. Non-conformities at the sterile manufacturing stage pose a threat to product quality, and the assessed risk to product quality and patient safety for the evaluated batches is high. A risk to patients' health or life cannot be excluded. Potential effects: infection, serious complications after parenteral administration, risk to health or life.
Egoropal
A routine FDA inspection revealed serious deficiencies in aseptic manufacturing. Non-conformities at the sterile production stage of an injectable product mean a high risk to product quality and patient safety. Potential effects: infections, severe complications after parenteral administration, lack of treatment safety.
Carmustine Accord
The solvent component of the medicine does not meet quality requirements: in the test of the "residue on evaporation" parameter, the National Medicines Institute found a several-fold exceedance of the allowable residue. Potential effects: contamination of the infusion solution, possible toxic effects, treatment complications, lack of therapy safety.
Egoropal
A routine FDA inspection revealed serious deficiencies in aseptic manufacturing processes; the assessed risk to product quality and patient safety for aseptically filled batches on the market is high. The product is a solution for injection (parenteral product). Potential effects: infections, poisoning, severe complications after parenteral administration, lack of therapeutic efficacy.
Palifren Long
An FDA inspection at the manufacturer found non-compliance in sterile/aseptic processing and procedures, implying a potential risk to the quality of these sterile medicinal products. Potential effects: injection-related infections, systemic complications, life-threatening events.
Palifren Long
An FDA inspection at the manufacturer revealed non-compliance in sterile and aseptic processing and procedures, posing a risk to the quality and sterility of injectable medicinal products. Potential effects: infection, loss of sterility, serious injection-related complications.
Palifren Long
During an FDA inspection at the manufacturer, non-compliances in sterile/aseptic processing and procedures were detected, indicating a risk to the quality and sterility of medicinal products administered by injection. Potencjalne skutki: infections, post-procedural complications, lack of sterility of the intramuscularly administered drug.
Egoropal
Routine FDA inspection revealed serious deficiencies in aseptic manufacturing processes; a high risk to product quality and patient safety was assessed for aseptically filled batches, which are solutions for injection (parenteral products). Potential effects: infections, complications after parenteral administration, lack of drug sterility.
Palifren Long
An FDA inspection at the manufacturer revealed non-compliances in "sterile/aseptic processing and procedures", posing a risk to the quality of sterile medicinal products intended for injection. Potential effects: infections, complications after parenteral administration, lack of treatment safety.
Clarithromycin Adamed
The active substance Clarithromycin used to manufacture the recalled batches was falsified and its quality is not confirmed, which for a product in the form of a solution for infusion may mean increased risk to patients' health. Potential effects: lack of treatment efficacy, unpredictable adverse reactions, severe systemic complications.
Clarithromycin hameln
Lack of confirmed compliance of the active substance quality with GMP requirements in an intravenously administered medicine (infusion solution, parenteral product), making it impossible to guarantee the safety and efficacy of this batch. Potential effects: lack of therapeutic efficacy, adverse reactions, complications, risk to patients' health or life.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.